SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate whether the token is a long-term utility play or a failing project amid ongoing price stagnation and leadership transitions. While some community members remain committed to accumulating through the dip, others are expressing significant frustration over lack of communication and constant downward pressure on the token's value.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is drawing intense community attention as traders debate its long-term viability against other meme coins, with many discussing its unique holding overlaps with projects like Updog. While some investors view the current price action as a buying opportunity, others remain skeptical about the asset's underlying value and volatility.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors rotate into defensive healthcare names while the stock demonstrates strong momentum, further bolstered by positive clinical data for its lung cancer treatments and ongoing pipeline expansion. The community is actively discussing the company's strategic positioning to mitigate upcoming patent expirations through acquisitions and high-profile collaborations within the oncology space.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is currently facing significant selling pressure as investors react to the firm capping quarterly withdrawals from one of its major private credit funds following record redemption requests. The news has sparked wider community concerns about potential liquidity stress and systemic risk within the private credit market, drawing comparisons to past financial downturns.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF (MAGS) is facing intense scrutiny as a new bearish MACD crossover fuels community concerns about a potential correction. Investors are actively debating the sustainability of massive AI-driven capital expenditures versus slowing mega-cap momentum, while many look for rotation opportunities into defensive sectors or smaller-cap stocks.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The PEPE community is currently polarized by heated debates over political ideologies, overshadowing typical price action discussions. While some traders continue to focus on accumulation strategies and potential meme-coin cycles, others are increasingly frustrated by the shift in board sentiment away from market-related analysis.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. The firm's solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. Its customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. The firm's regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. Its customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems is experiencing a surge in interest as investors digest strong quarterly earnings that showcased consistent revenue growth and a commitment to AI-driven industry cloud solutions. The community is actively weighing the company's long-term competitive positioning and the impact of its strategic pivot to the Vault platform against ongoing market debates regarding SaaS valuations and enterprise software demand.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is gaining attention as investors react to a strategic expansion into Walmarts ecosystem, positioning the company as a broader digital healthcare infrastructure provider. Community sentiment is mixed, with some traders debating the potential for a short squeeze due to high short interest, while long-term investors emphasize the value of its global data footprint and AI-driven growth initiatives.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is currently trending as community members speculate on the upcoming Goliath mainnet launch and its potential impact on enterprise-grade institutional infrastructure. While some investors express optimism regarding long-term accumulation and staking utility, others remain deeply skeptical, frequently debating the project's transparency and citing a pattern of volatility they describe as pump-and-dump activity.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is trending as investors focus on its v4 launch and a revenue-sharing model that distributes decentralized GPU network earnings to stakers. The community is heavily focused on the high percentage of supply currently locked in long-term staking, which many view as a bullish catalyst for supply scarcity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why

XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing...

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...

Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...

Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE

Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options...

Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton Conference

Xenon Pharmaceuticals (NASDAQ:XENE) provided an update on its clinical and pipeline progress at the Bloom Burton conference, with CEO Ian Mortimer highlighting recent Phase III results for lead program azetukalner, plans for regulatory filings, and continued expansion into psychiatry and pain.

Lead...

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$59.74
Prev Close	$56.78
Open	$56.97
Dividend Yield	0.00%
50-Day Moving Average	$54.83
Beta	0.86
Avg. Volume	1.16M
PE Ratio	-12.07

52-Week High	$63.95
52-Week Low	$30.00
Market Capitalization	$5.77B
EPS (Annual)	-$4.36
Price to Book	4.10
Revenue Per Employee	$20,270.27

Feed

News

Sentiment

Earnings

Fundamentals

Info

XENEXenon Pharmaceuticals Inc

Latest XENE News